Women’s Health

Abstract

80% of U.S. women experience imbalance of their reproductive hormones often causing conditions such as endometriosis, PCOS, PID, chronic yeast infections and chronic bacterial vaginosis. 1 in 6 women globally also experience infertility and 1.3 million women in the U.S. are experiencing menopause annually. The aim of BioBalance is to advance female reproductive healthcare and empower women by developing research and diagnostic models using cervical mucus qualitative metrics and quantitative hormone analytics. By doing this BioBalance hopes to be able to detect conditions resulting from hormonal imbalance such as those aforementioned. The device will be marketed for anyone with female reproductive organs who seek a personalized understanding of their menstrual cycle. Currently, the market for cycle-tracking or fertility-tracking devices is experiencing a compound annual growth rate of ~10.8% by 2032 with a current market size of around $475 million USD. The competition in this market is not significant especially for BioBalance’s unique design concept that goes beyond fertility tracking.

Video